Biotech Values

[walldiver]

I see both sides of this issue as well. On the one hand, it would have been nice to see the interim 28-month survival data from 9902A, and to know how many patients at that point in time still had immature data. On the other hand, 9901 is being presented again by Dr. Small, and I think that DNDN wants any spotlight on Provenge at Big ASCO to be a positive one. The negative progression data from 9902A would probably muddy the waters, especially considering the strong, loud, and persistent short position in the stock.